Sutro Biopharma (STRO) Accumulated Expenses (2017 - 2025)

Sutro Biopharma's Accumulated Expenses history runs 9 years deep, the most recent figure standing at $12.6 million for Q4 2025.

• In Q4 2025, Accumulated Expenses fell 59.69% year-over-year to $12.6 million; the TTM figure through Dec 2025 stood at $12.6 million (down 59.69% YoY), while the FY2025 annual figure was $12.6 million, down 59.69% from the prior year.
• Accumulated Expenses came in at $12.6 million for Q4 2025 at Sutro Biopharma, down from $13.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $38.5 million in Q4 2023 to a low of $4.5 million in Q1 2021.
• A 5-year average of $15.3 million and a median of $11.7 million in 2025 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses surged 204.58% in 2024 and slumped 69.39% in 2025, its largest moves.
• Sutro Biopharma's Accumulated Expenses stood at $8.4 million in 2021, then jumped by 56.42% to $13.1 million in 2022, then soared by 192.75% to $38.5 million in 2023, then declined by 18.77% to $31.2 million in 2024, then sank by 59.69% to $12.6 million in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $12.6 million, $13.2 million, and $11.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison